A closer look at BCRX’s price-to-free cash flow ratio

Biocryst Pharmaceuticals Inc (BCRX)’s stock is trading at $8.57 at the moment marking a fall of -0.17% from the last session close. As of this writing, shares are priced at -24.18% less than their 52-week high of $11.31, and 42.56% over their 52-week low of $6.01. Based on the past 30-day period, the stock price is -16.21% below the high and +0.71% above the low.

The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, BCRX’s SMA-200 is $8.34.

Further, it is important to consider BCRX stock ratios, particularly its price-to-sales ratio over the past twelve months, which stands at 3.56.

How does Biocryst Pharmaceuticals Inc (BCRX) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 11 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.64 in simple terms.

Biocryst Pharmaceuticals Inc (BCRX): Earnings History

If we examine Biocryst Pharmaceuticals Inc’s recent earnings history, in the last quarter ended on 3/31/2025, it posted adjusted earnings per share of $0, slashing the consensus of -$0.05. In other words, it beat the consensus by $0.05, resulting in a 100.00% surprise. In the 3 months period before the previous quarter which was closed on 3/31/2025, the stock recorded adjusted earnings per share of $0 in contrast with the Outlook of -$0.05. That was a difference of $0.05 and a surprise of 100.00%.

Biocryst Pharmaceuticals Inc (BCRX): Earnings History

Most analysts expect public companies to report earnings and revenue in line with their projections, but sometimes these figures vary from what they actually expected. In the current quarter, the company had earnings predictions made by 5 different analysts, who are expecting earnings to fall in between the range of 0.10 and 0.00 with an average Earnings Estimate of 0.03 which is in contrast with the last year earnings estimate of -0.06 and also replicates 150.00% growth rate year over year.

Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) Ownership Details

I will give a breakdown of the key shareholders in Biocryst Pharmaceuticals Inc (BCRX). Recent figures show that the company’s insiders hold 1.20% of shares. A total of 357 institutional investors hold shares in the company, making 85.56% of its stock and 86.59% of its float.

Mar 31, 2025 , it was reported that the Company’s largest institutional holder is Blackrock Inc. holding total of 22.77 shares that make 10.88% of the company’s total number of shares and are currently priced at 194.9 million.

The securities firm Vanguard Group Inc holds 21.66 shares of BCRX, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 10.35% , and the holding percentage of shares is valued at 185.41 million.

An overview of Biocryst Pharmaceuticals Inc’s technicals

In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Biocryst Pharmaceuticals Inc (BCRX) traded 3,263,182 shares per day, with a moving average of $9.18 and price change of -1.47. With the moving average of $9.96 and a price change of -2.52, about 4,267,729 shares changed hands on average over the past 50 days. Finally, BCRX’s 100-day average volume is 4,200,101 shares, alongside a moving average of $8.89 and a price change of -0.70.

Hot this week

Experts predict UiPath Inc’s (PATH) current quarter earnings growth rate

UiPath Inc (PATH)'s stock is trading at $12.48 at...

Analyzing GME’s current quarter earnings projections

Gamestop Corporation (GME)'s stock has witnessed a price declined...

Will Celsius Holdings Inc (CELH) meet earnings estimates this quarter?

Currently, Celsius Holdings Inc's (CELH) stock is trading at...

A look at CLSD’s current quarter earnings estimates

In the current trading session, Clearside Biomedical Inc's (CLSD)...

How analysts predict Dexcom Inc (DXCM) will perform this quarter?

Dexcom Inc (DXCM)'s stock is trading at $85.4 at...

Topics

Experts predict UiPath Inc’s (PATH) current quarter earnings growth rate

UiPath Inc (PATH)'s stock is trading at $12.48 at...

Analyzing GME’s current quarter earnings projections

Gamestop Corporation (GME)'s stock has witnessed a price declined...

Will Celsius Holdings Inc (CELH) meet earnings estimates this quarter?

Currently, Celsius Holdings Inc's (CELH) stock is trading at...

A look at CLSD’s current quarter earnings estimates

In the current trading session, Clearside Biomedical Inc's (CLSD)...

How analysts predict Dexcom Inc (DXCM) will perform this quarter?

Dexcom Inc (DXCM)'s stock is trading at $85.4 at...

OXY stock’s current quarter earnings estimates: What analysts predict?

Occidental Petroleum Corp (OXY)'s stock has witnessed a price...

What to expect from B2gold Corp’s (BTG) current quarter earnings?

Currently, B2gold Corp's (BTG) stock is trading at $3.38,...

GFAI’s price-to-cash ratio: How it affects the stock’s valuation.

In the current trading session, Guardforce AI Co Ltd's...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.